Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash & Equivalents (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Cash & Equivalents for 6 consecutive years, with $84.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 32.4% to $84.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $84.0 million through Dec 2025, down 32.4% year-over-year, with the annual reading at $84.0 million for FY2025, 32.4% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $84.0 million at Relay Therapeutics, down from $91.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $354.6 million in Q3 2022, with the low at $84.0 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $165.7 million, with a median of $148.6 million recorded in 2023.
  • Peak annual rise in Cash & Equivalents hit 273.49% in 2021, while the deepest fall reached 59.13% in 2021.
  • Over 5 years, Cash & Equivalents stood at $280.1 million in 2021, then plummeted by 45.81% to $151.8 million in 2022, then fell by 5.31% to $143.7 million in 2023, then dropped by 13.53% to $124.3 million in 2024, then plummeted by 32.4% to $84.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $84.0 million, $91.6 million, and $113.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.